A new analytical data report titled United States Prenatal Diagnostic Market has been published by Absolute Markets Insights. This report transmits a sophisticated abridgment of the statistical data that has been scrutinized on the basis of effective inquisitive techniques that include primary and secondary research. The precise data information has been studied by our perceptive team with the help of unparalleled applicable sales strategies that can improve the performance of market industries. The compelling structure of the United States Prenatal Diagnostic market positively attributes to the advancement of industries. Furthermore, the report also covers other crucial market restraints. These restraints provide further insights into threats and challenges in the business.
Key Highlights of the Report:
• Market Performance
• Market Outlook
• Porter’s Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• The Impact of COVID-19 on the Market
• Value Chain Analysis
• Structure of the Market
• Comprehensive mapping of the competitive landscape
The major key pillars for United States Prenatal Diagnostic market are listed below: Laboratory Corporation of America Holdings, Eurofins NTD, LLC, Abbott Laboratories, Hologic Inc., Illumina, Inc., Natera, Inc., PerkinElmer, Inc., Sequenom, Inc., Ariosa Diagnostics, Inc., and Ravgen. Inc. amongst others.
For more information about this report visit: https://www.absolutemarketsinsights.com/reports/United-States-Prenatal-Diagnostic-Market-2018-2026-17
Prenatal diagnostics is used for testing the fetus before birth to determine certain hereditary disorders, for instance, Down's syndrome, hereditary sicknesses, chromosome abnormalities, neural tube defects, and other conditions. If high-risk is identified with the birth of a child, it can be assisted by conducting hereditary testing, common testing, and screening. The United States Prenatal Diagnostic Market was valued at USD 527.5 Mn in 2017 and is expected to reach US$ 1,429.5 Mn by 2022.
United States Prenatal Diagnostic Market Segmentation:
Prenatal Diagnostic Market, By Test Type
On the basis of test type, MaterniT21 PLUS Segment represented a major share in the U.S. Prenatal Diagnostic Market in 2016. The MaterniT21 PLUS test is indicated for use in pregnant women with increased risk for chromosomal aneuploidy. It analyzes circulating cell-free DNA extracted from a maternal blood sample. Rise in maternal age, and growing incidence of genetic abnormalities in newborns are the most significant drivers of these tests. Moreover, increased market penetration and competitive marketing methodologies by companies are further boosting the growth of these tests.
United States Prenatal Diagnostic Market
It has been reported that there are 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States. The test is mainly to analyze the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. Increasing rate of high-risk pregnancies and rising average age for childbearing is driving the market growth particularly in developed countries such as the United States. With better advertising procedures and positioning, major companies are planning to venture in this area. Steady government research activities and increasing discretionary cash flow are some of the elements supplementing the prenatal diagnostics market in the U.S.
Contact Us:
Contact Name: Shreyas Tanna
Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com
Phone: IN +91-7400-24-24-24, US +1-510-420-1213
Website: www.absolutemarketsinsights.co...